Previous 10 | Next 10 |
The following slide deck was published by Baudax Bio, Inc. in conjunction with this event. For further details see: Baudax Bio (BXRX ) Investor Presentation - Slideshow
MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, wi...
Baudax Bio has been a miserable investment so far as the share price remains under $1.00 per share and the market cap continues to deteriorate. The company recently reported abysmal Q2 earnings with a big miss on EPS and revenue. However, the company did reveal some encouraging commer...
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, wi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re getting ready for another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday. Source: Shutterstock But hold on just a second. Before that, make ...
Baudax Bio, Inc. (BXRX) Q2 2021 Earnings Conference Call August 05, 2021 08:00 AM ET Company Participants Claudia Styslinger - Investor Relations Gerri Henwood - President & Chief Executive Officer Rick Casten - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenh...
The following slide deck was published by Baudax Bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Baudax Bio, Inc. 2021 Q2 - Results - Earnings Call Presentation
Baudax Bio (NASDAQ:BXRX): Q2 GAAP EPS of -$0.21 misses by $0.01. Revenue of $0.2M (-42.9% Y/Y) misses by $0.27M. Press Release For further details see: Baudax Bio EPS misses by $0.01, misses on revenue
Total Number of ANJESO ® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020 ANJESO ® Demand Showing Strong Growth Based on Several Key Quarter-Over-Quarter Metrics (Second Quarter of 2021 Compared to...
MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, recently announced that it has adjourned its Special Meeting of Share...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023